Medicine and Dentistry
Pediatrics
100%
Dermatitis
64%
Cutaneous Leishmaniasis
64%
Pediatrics Patient
53%
Exanthem
46%
Oncology
43%
Side Effect
42%
Adverse Event
36%
Psoriasis
36%
Leishmania Major
34%
Patient Referral
34%
Retrospective Study
30%
Infection
28%
Disease
27%
Immune Deficiency
24%
Retrospective Cohort Study
24%
Skin Infection
24%
Pleura Effusion
21%
Mycosis fungoides
21%
Meglumine Antimoniate
21%
Severe Acute Respiratory Syndrome Coronavirus 2
21%
Immunotherapy
21%
COVID-19
21%
Mastocytosis
21%
Capillary Hemangioma
21%
Intensive Care Unit
21%
Calcineurin Inhibitor
21%
Patient with Inflammatory Bowel Disease
21%
Physiological Monitoring
21%
Complement
21%
Tuberous Sclerosis
21%
Dermatological Agent
21%
Cytokinesis
21%
Prurigo
21%
Papular Rash
21%
Propranolol
21%
Measles Like Rash
21%
Medical Decision Making
21%
Miltefosine
21%
Arthralgia
21%
Mast Cell
21%
TNF Inhibitor
21%
Targeted Therapy
21%
Intensive Care
21%
Pigmented Purpuric Dermatosis
21%
Sodium Stibogluconate
21%
Cell-Free DNA
21%
Leishmaniasis
21%
Nevus
21%
Messenger RNA
21%
Keyphrases
Cutaneous Leishmaniasis
64%
Pediatric Patients
56%
Pediatric
49%
Israel
43%
Lung Transplantation
43%
Pediatric Psoriasis
43%
Arthritis
37%
Leishmania Major
36%
Rash
35%
Tacrolimus
34%
Tertiary Care Hospital
31%
Treatment Options
29%
Atopic Dermatitis
24%
Methotrexate
24%
Safety Profile
24%
Referral Center
24%
Retrospective Cohort
23%
Old World Cutaneous Leishmaniasis
23%
Leishmania Tropica
23%
Pleural Fluid
21%
Mycosis Fungoides
21%
Early Signs
21%
Epidermal Nevus
21%
EGFR Inhibitors
21%
Maculopapular Rash
21%
Pleural Effusion
21%
Diagnostic Algorithm
21%
Meglumine Antimoniate
21%
Tuberous Sclerosis
21%
Mastocytosis
21%
Toddlers
21%
Multicenter Retrospective Cohort Study
21%
Retrospective multicenter Study
21%
SARS-CoV-2 Infection
21%
Solid Organ Transplant Recipients
21%
Day Care
21%
Pemphigus
21%
Propranolol
21%
Infantile Hemangioma
21%
COVID-19 mRNA Vaccination
21%
Diagnostic Value
21%
Complement Components
21%
Randomized Clinical Trial
21%
Periorificial Dermatitis
21%
Topical Calcineurin Inhibitors
21%
Hospitalization
21%
Papular
21%
Subacute Prurigo
21%
Papular Dermatitis
21%
Morbilliform Rash
21%